Treatment settings and metabolic monitoring for people experiencing first-episode psychosis

Journal of Psychosocial Nursing and Mental Health Services

Volumn 48, Issue 9, 2010, Pages 44-49

  Batscha, Catherine ^a   Schneiderhan, Mark E ^c   Kataria, Yachana ^b   Rosen, Cherise ^a   Marvin, Robert W ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMAN; MALE; MASS SCREENING; METABOLIC SYNDROME X; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PROCEDURES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AMBULATORY CARE FACILITIES; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CHICAGO; DRUG MONITORING; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; MALE; MASS SCREENING; METABOLIC SYNDROME X; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 77957365291     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20100730-03     Document Type: Article

References (15)

1. Attux, C., Quintana, M.I., & Chaves, A.C. (2007). Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Revista Brasileira De Psiquiatria, 29, 346-349.
2. Birchwood, M. (2003). Pathways to emotional dysfunction in first-episode psychosis. British Journal of Psychiatry, 182, 373-375.
3. Buse, J.B., Cavazzoni, P., Hornbuckle, K., Hutchins, D., Breier, A., & Jovanovic, L. (2003). A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 56, 164-170.
4. Covell, N.H., Finnerty, M.T., & Essock, S.M. (2008). Implications of CATIE for mental health services researchers. Psychiatric Services, 59, 526-529.
5. Davis, K. (2009). Emphasizing holistic care: A mental healthcare provider integrates physical healthcare into its services. Behavioral Healthcare, 29(3), 38-39. Retrieved from http://www.behavioral.net
6. De Hert, M., Schreurs, V., Sweers, K., Van Eyck, D., Hanssens, L., Sinko, S., et al. (2008). Typical and atypical antipsychotics differentially affect long incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophrenia Research, 101, 295-303.
7. Eckel, R.H., Grundy, S.M., & Zimmet, P.Z. (2005). The metabolic syndrome. The Lancet, 365,1415-1418.
8. Haupt, D.W., Rosenblatt, L.C., Kim, E., Baker, R.A., Whitehead, R., & Newcomer, J.W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry, 166, 345-353.
9. McEvoy, J.P., Meyer, J.M., Goff, D.C., Nasrallah, H.A., Davis, S.M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32.
10. Newcomer, J.W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19(Suppl. 1), 1-93.
11. Parks, J., Svendsen, D., Singer, P., & Foti, M.E. (Eds.). (2006, October). Morbidity and mortality in people with serious mental illness. Retrieved from the National Association of State Mental Health Program Directors website: http://www.nasmhpd.org/general_files/publications/med_directors_pubs/technical%20report%20on%20morbidity%20and%20mortaility%20-%20final%2011-06.pdf
12. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. The Australian and New Zealand Journal of Psychiatry, 39(1-2), 1-30.
13. Schneiderhan, M., Batscha, C., & Rosen, C. (2009). Results of point-of-care glucose testing and basic metabolic screening in outpatients on antipsychotic agents. Pharmacotherapy, 29, 975-987.
14. Schneiderhan, M.E., Cernohous, T., Miller, P.S., Fike, J., Hovland, J., Traynor, A.P., et al. (2009, April). Can point-of-care testing (POCT) and assistance from medication therapy management (MTM) pharmacists improve early detection and management of metabolic syndrome due to antipsychotic agents? Poster presented at the meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, FL.
15. Spencer, E., Birchwood, M., & McGovern, D. (2001). Management of first-episode psychosis. Advances in Psychiatric Treatment, 7, 133-140. Retrieved from http://apt.rcpsych.org/cgi/content/full/7/2/133